BUZZ-Jazz Pharma jumps after cancer drug meets main goal in late-stage study
I'm PortAI, I can summarize articles.
Jazz Pharmaceuticals' shares rose 13.4% premarket after its cancer drug, Ziihera, met main goals in a late-stage study for stomach cancer treatment. The study showed significant improvements in survival rates. Jazz shares rights with Zymeworks, whose shares also increased by 43.52% premarket. Jazz plans to submit a marketing application to the FDA in H1 2026. Ziihera is already approved for biliary tract cancer treatment. As of last close, Jazz shares are up 14.6% and Zymeworks 26.5% YTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments